{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-107426","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.381491+00:00","generated_at":"2026-05-16T23:35:22.135822+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Iovance Q3 revenue $68M (+13% QoQ), margin 43%; lifileucel NSCLC data durable","bullets":["Q3 2025 product revenue ~$68M, up 13% sequentially; gross margin 43% on ~$39M cost of sales.","Cash and investments ~$307M; expected to fund operations into Q2 2027.","Full-year 2025 revenue guidance reaffirmed at $250-300M.","Lifileucel in NSCLC: ORR 26%, median DOR not reached at >25 months; IOV-LUN-202 enrollment to complete in 2026.","Amtagvi now at >80 U.S. authorized treatment centers; Health Canada approval in August 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-107426","json":"https://secwatch.observer/filing/0001104659-25-107426.json","markdown":"https://secwatch.observer/filing/0001104659-25-107426.md","text":"https://secwatch.observer/filing/0001104659-25-107426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465925107426/0001104659-25-107426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465925107426/tm2530236d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:35:22.135822+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}